CLFeb 25

MEDSYN: Benchmarking Multi-EviDence SYNthesis in Complex Clinical Cases for Multimodal Large Language Models

arXiv:2602.21950v1h-index: 7Has Code
Originality Incremental advance
AI Analysis

This addresses the need for better benchmarks in medical AI to assess real-world clinical complexity, though it is incremental as it builds on existing MLLM evaluation methods.

The paper tackles the problem of evaluating multimodal large language models (MLLMs) in complex clinical scenarios by introducing MEDSYN, a benchmark with up to 7 visual evidence types per case, and finds that while top models match human experts in differential diagnosis generation, they show a larger performance gap in final diagnosis selection due to overreliance on textual evidence and cross-modal utilization issues.

Multimodal large language models (MLLMs) have shown great potential in medical applications, yet existing benchmarks inadequately capture real-world clinical complexity. We introduce MEDSYN, a multilingual, multimodal benchmark of highly complex clinical cases with up to 7 distinct visual clinical evidence (CE) types per case. Mirroring clinical workflow, we evaluate 18 MLLMs on differential diagnosis (DDx) generation and final diagnosis (FDx) selection. While top models often match or even outperform human experts on DDx generation, all MLLMs exhibit a much larger DDx--FDx performance gap compared to expert clinicians, indicating a failure mode in synthesis of heterogeneous CE types. Ablations attribute this failure to (i) overreliance on less discriminative textual CE ($\it{e.g.}$, medical history) and (ii) a cross-modal CE utilization gap. We introduce Evidence Sensitivity to quantify the latter and show that a smaller gap correlates with higher diagnostic accuracy. Finally, we demonstrate how it can be used to guide interventions to improve model performance. We will open-source our benchmark and code.

Foundations

The foundational work for this paper's niche, ranked by how specifically the neighbourhood builds on it — not by global fame.

Your Notes